WASHINGTON, June 8, 2021 /PRNewswire/ -- The
Antimicrobials Working Group (AWG) announced today the addition of
Crestone, Inc. (Crestone) to its coalition of companies with the
mission to combat drug resistant infections and spur life-saving
innovations. This new addition brings AWG's membership to 12
antimicrobial drug companies.
Crestone is a clinical stage biopharmaceutical company focused
on inventing and developing novel small molecule drugs for serious
bacterial infections, including C. difficile Infection
(CDI), resistant Gram-positive infections such as
methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus (VRE), and chronic
infections such as nontuberculous mycobacterial (NTM) disease.
Their lead product candidate, CRS3123, for the treatment of CDI, is
in Phase 2 clinical development sponsored by NIAID (NIH) and has
been granted Qualified Infectious Disease Product (QIDP) and Fast
Track designation by the FDA.
"The development of safe and effective antimicrobials is an
important component in ensuring that physicians are equipped with
the best treatment options for dangerous, and hard to treat,
drug-resistant pathogens. Crestone has demonstrated a commitment to
developing novel small molecule drugs for serious bacterial
infections," said Ted Schroeder,
Chief Executive Officer of Nabriva Therapeutics and Chairman of
AWG. "We are excited to have Urs
Ochsner and his team join our coalition as we continue to
push for critical legislative and regulatory changes that will
stabilize the antimicrobial ecosystem, support innovation, and
provide patients with the treatments they need to survive life
"The current pandemic reminds us of the need to prepare now to
combat emerging infectious diseases. This includes the specter of
losing antibiotics due to resistance; a major threat to modern
medicine," said Urs Ochsner, Ph.D.,
Founder and CEO of Crestone, Inc. "We are glad to be a part of AWG,
a most important platform to team up with like-minded companies
against resistant bacterial infections to develop safe and novel
life-saving medicines for the future."
All pharmaceutical and biotechnology companies developing new
antimicrobial therapeutics and diagnostic devices are eligible for
consideration of membership in AWG. If you are interested in
learning more about becoming a member of AWG, please contact us
About Crestone's Pipeline.
CRS3123 for the treatment
of CDI currently is in Phase 2 clinical development. The compound
targets methionyl-tRNA synthetase (MetRS) and has demonstrated
accumulation in the gut, inhibition of toxin and spore formation,
and a very narrow spectrum of activity.
CRS0540 is in preclinical development. The mechanistically novel
oral/IV antibacterial drug candidate targets PolC, the catalytic
subunit of the replicative DNA polymerase in Gram-positive
bacteria. It is intended for treatment of infections caused by
CRS0393 is in preclinical development for the treatment of
pulmonary NTM disease via inhaled and/or oral therapy. It is
a selective antibacterial compound targeting the essential
mycobacterial MmpL3 enzyme.
About The Antimicrobials Working Group
AWG was founded
in 2012 with the vision of utilizing collective power to improve
the regulatory, investment, and commercial environment for emerging
infectious disease companies. Today, AWG is comprised of twelve
antimicrobials companies: Cidara Therapeutics Inc.
(NASDAQ: CDTX), Crestone, Inc., Entasis Therapeutics Inc.,
Iterum Therapeutics Ltd. (NASDAQ: ITRM), Melinta Therapeutics
Inc. (NASDAQ: MLNT), Nabriva Therapeutics US Inc.
(NASDAQ: NBRV), Paratek Pharmaceuticals Inc.
(NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc.
(NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ: SMMT)
(AIM: SUMM), UTILITY therapeutics Ltd., and Venatorx
For more information,
About The Conafay Group
The Conafay Group, led
by Stephen R. Conafay, Principal, is a life-sciences
government relations firm based in Washington D.C. that
serves as Washington counsel and coalition manager for
For more information, visit: www.conafaygroup.com
SOURCE Antimicrobials Working Group (AWG)